Biologics and Still Disease

This chapter explores the impact of biologics, such as IL-1 and IL-6 inhibitors, on inflammatory markers and outcomes in patients with Still's disease, shedding light on improved outcomes and reduced inflammatory markers. It also touches on the connection between obstructive sleep apnea and gout development, as well as the increased risk of autoimmune diseases post-SARS-CoV-2 infection and the diagnostic utility of MRI in inflammatory myositis.